Jeil Pharmaceutical and Amgen Korea Sign Joint Sales Agreement for Lipid-Lowering Agent 'Lepata'

[Asia Economy Reporter Lee Gwan-ju] Jeil Pharmaceutical and Amgen Korea announced on the 7th that they have signed a domestic co-promotion agreement for the lipid-lowering agent "Repatha" (generic name evolocumab) for patients with atherosclerotic cardiovascular disease and hypercholesterolemia.

Under this agreement, Jeil Pharmaceutical and Amgen Korea will jointly conduct sales and marketing activities for Repatha at tertiary general hospitals and general hospitals. Sales and marketing activities targeting clinics and smaller hospitals will be solely handled by Jeil Pharmaceutical.

Repatha is a PCSK9 inhibitor that lowers blood LDL cholesterol (LDL-C) levels by inhibiting the activity of the PCSK9 protein, which degrades LDL-C receptors, thereby increasing the recycling rate of LDL-C receptors. It was approved in Korea in 2017, and based on therapeutic efficacy and safety confirmed through clinical studies, it received additional indications in August 2018 for ▲atherosclerotic cardiovascular disease ▲primary hypercholesterolemia and mixed dyslipidemia.

Seong Seok-je, CEO of Jeil Pharmaceutical, said, "Through this co-promotion agreement, we expect that Jeil Pharmaceutical’s core competitiveness in excellent sales capabilities and differentiated marketing strategies will create synergy with Amgen’s innovative products and clinical data," adding, "We will strive to provide the clinical benefits of Repatha to more cardiovascular disease patients in the future."

No Sang-kyung, CEO of Amgen Korea, stated, "Repatha is Amgen’s flagship product in the cardiovascular disease treatment sector, offering new treatment opportunities to patients who had limitations in reducing cardiovascular risk with existing treatment options due to its innovative mechanism," and added, "We hope that the clinical benefits of Repatha will be delivered to more atherosclerotic cardiovascular disease patients and healthcare professionals in Korea, establishing Repatha firmly as a new standard of care."

This content was produced with the assistance of AI translation services.